US6605648B1
(en)
*
|
1999-04-06 |
2003-08-12 |
Phillips Plastics Corporation |
Sinterable structures and method
|
US20040266673A1
(en)
*
|
2002-07-31 |
2004-12-30 |
Peter Bakis |
Long lasting natriuretic peptide derivatives
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
US6887470B1
(en)
*
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
WO2000069911A1
(en)
*
|
1999-05-17 |
2000-11-23 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
US6849714B1
(en)
*
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
US6447772B1
(en)
*
|
1999-10-01 |
2002-09-10 |
Klaire Laboratories, Inc. |
Compositions and methods relating to reduction of symptoms of autism
|
IL155812A0
(en)
*
|
2000-12-07 |
2003-12-23 |
Lilly Co Eli |
Glp-1 fusion proteins
|
JP2004520395A
(ja)
|
2001-02-02 |
2004-07-08 |
コンジュケム,インコーポレーテッド |
長期持続性成長ホルモン放出因子誘導体
|
DE60226702D1
(de)
|
2001-02-16 |
2008-07-03 |
Conjuchem Biotechnologies Inc |
Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
DE60229677D1
(de)
|
2001-05-31 |
2008-12-11 |
Conjuchem Biotechnologies Inc |
Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
|
AU2002317599B2
(en)
|
2001-07-31 |
2008-04-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
US6642003B2
(en)
|
2001-08-02 |
2003-11-04 |
Cedars-Sinai Medical Center |
Human glucose-dependent insulin-secreting cell line
|
US20070031440A1
(en)
*
|
2001-08-30 |
2007-02-08 |
Prior Christopher P |
Modified transferin-antibody fusion proteins
|
US7176278B2
(en)
*
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
US20030226155A1
(en)
*
|
2001-08-30 |
2003-12-04 |
Biorexis Pharmaceutical Corporation |
Modified transferrin-antibody fusion proteins
|
US20040023334A1
(en)
*
|
2001-08-30 |
2004-02-05 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins
|
US8129504B2
(en)
|
2001-08-30 |
2012-03-06 |
Biorexis Technology, Inc. |
Oral delivery of modified transferrin fusion proteins
|
EP1463751B1
(en)
*
|
2001-12-21 |
2013-05-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2003059934A2
(en)
*
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1487995A4
(en)
*
|
2002-02-13 |
2006-08-02 |
Medbridge Inc |
PROTEIN CARRIER SYSTEM FOR THERAPEUTIC OLIGONUCLEOTIDES
|
EP2409569B1
(en)
*
|
2002-02-20 |
2017-08-16 |
Emisphere Technologies, Inc. |
Method for administering GLP-1 molecules
|
US7141240B2
(en)
*
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
WO2003103572A2
(en)
*
|
2002-06-04 |
2003-12-18 |
Eli Lilly And Company |
Modified glucagon-like peptide-1 analogs
|
EP1837031B1
(en)
*
|
2002-06-07 |
2009-10-14 |
Waratah Pharmaceuticals, Inc. |
Compositions and methods for treating diabetes
|
JP5685355B2
(ja)
|
2002-07-04 |
2015-03-18 |
ジーランド ファーマ アクティーゼルスカブ |
Glp−1および糖尿病の処置方法
|
AU2003262886A1
(en)
*
|
2002-08-30 |
2004-03-19 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
|
EA007918B1
(ru)
*
|
2002-09-24 |
2007-02-27 |
Франтиэ Биотекнолоджиз Ко., Лтд. |
Пептидные производные-ингибиторы слияния при вич-инфекции
|
CA2500295A1
(en)
|
2002-10-02 |
2004-04-29 |
Zealand Pharma A/S |
Stabilized exendin-4 compounds
|
US20040229810A1
(en)
*
|
2002-10-22 |
2004-11-18 |
Antonio Cruz |
Gastrin compositions and formulations, and methods of use and preparation
|
US7790681B2
(en)
*
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
US20040209803A1
(en)
*
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
WO2004060387A1
(en)
*
|
2002-12-27 |
2004-07-22 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
US7655618B2
(en)
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
US20070060512A1
(en)
*
|
2003-03-04 |
2007-03-15 |
Homayoun Sadeghi |
Dipeptidyl-peptidase protected protein
|
EP1608317B1
(en)
|
2003-03-25 |
2012-09-26 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
KR101198346B1
(ko)
*
|
2003-04-08 |
2012-11-06 |
노보 노르디스크 에이/에스 |
크로마토그래피 고정상의 재생
|
WO2004089985A1
(en)
*
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
EP1617888B1
(en)
|
2003-04-23 |
2019-06-12 |
Valeritas, Inc. |
Hydraulically actuated pump for long duration medicament administration
|
GEP20084406B
(en)
|
2003-05-30 |
2008-06-25 |
Ranbaxy Lab Ltd |
Substituted pyrrole derivatives and their use as hmg-co inhibitors
|
CN1802386B
(zh)
|
2003-06-12 |
2010-12-15 |
伊莱利利公司 |
Glp-1类似物融合蛋白质
|
CN1964989B
(zh)
*
|
2003-07-25 |
2012-02-01 |
康久化学生物技术公司 |
长效胰岛素衍生物及其方法
|
EP2085406A1
(en)
*
|
2003-07-25 |
2009-08-05 |
ConjuChem Biotechnologies Inc. |
Long lasting insulin derivatives and methods thereof
|
US7579357B2
(en)
*
|
2003-08-13 |
2009-08-25 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US20060205037A1
(en)
*
|
2003-08-28 |
2006-09-14 |
Homayoun Sadeghi |
Modified transferrin fusion proteins
|
WO2005021579A2
(en)
*
|
2003-08-28 |
2005-03-10 |
Biorexis Pharmaceutical Corporation |
Epo mimetic peptides and fusion proteins
|
WO2005021026A2
(en)
*
|
2003-08-29 |
2005-03-10 |
Amylin Pharmaceuticals, Inc. |
Methods for treating or ameliorating ghrelin-associated diseases and disorders
|
JP2007505121A
(ja)
*
|
2003-09-08 |
2007-03-08 |
武田薬品工業株式会社 |
ジペプチジルぺプチダーゼ阻害剤
|
US7214190B1
(en)
|
2003-09-09 |
2007-05-08 |
Kitchener Clark Wilson |
Apparatus and method for noninvasive monitoring of analytes in body fluids
|
JP2007537142A
(ja)
*
|
2003-12-18 |
2007-12-20 |
ノボ ノルディスク アクティーゼルスカブ |
アルブミン様物質に結合した新規のglp−1類似物
|
US20060286129A1
(en)
*
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
WO2005072045A2
(en)
*
|
2004-01-30 |
2005-08-11 |
Waratah Pharmaceuticals, Inc. |
The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
|
EP1729795B1
(en)
|
2004-02-09 |
2016-02-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
CN102127057A
(zh)
*
|
2004-03-15 |
2011-07-20 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
DE602005022239D1
(de)
*
|
2004-04-23 |
2010-08-19 |
Conjuchem Biotechnologies Inc |
Festphase zur Verwendung in einem Verfahren zur Reinigung von Albuminkonjugaten
|
CN1318587C
(zh)
*
|
2004-04-30 |
2007-05-30 |
成都芝田生物工程有限公司 |
酰胺化Exendin-4多肽的重组制备方法
|
US9089636B2
(en)
|
2004-07-02 |
2015-07-28 |
Valeritas, Inc. |
Methods and devices for delivering GLP-1 and uses thereof
|
AU2012202855B2
(en)
*
|
2004-09-03 |
2015-02-26 |
Philipps-Universitat Marburg |
GLP-1 and exendin related invention
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
EP1799711B1
(en)
|
2004-10-07 |
2012-06-20 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
JP2008515856A
(ja)
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性glp−1化合物
|
US20080125361A1
(en)
*
|
2004-11-12 |
2008-05-29 |
Novo Nordisk A/S |
Stable Formulations Of Peptides
|
JP2008524331A
(ja)
*
|
2004-12-21 |
2008-07-10 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼ阻害剤
|
US8716221B2
(en)
*
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
TWI376234B
(en)
*
|
2005-02-01 |
2012-11-11 |
Msd Oss Bv |
Conjugates of a polypeptide and an oligosaccharide
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US8603972B2
(en)
|
2005-03-18 |
2013-12-10 |
Novo Nordisk A/S |
Extended GLP-1 compounds
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
EP2330124B1
(en)
*
|
2005-08-11 |
2015-02-25 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
ZA200802857B
(en)
|
2005-09-14 |
2009-09-30 |
Takeda Pharmaceutical |
Dipeptidyl peptidase inhibitors for treating diabetes
|
PE20070622A1
(es)
*
|
2005-09-14 |
2007-08-22 |
Takeda Pharmaceutical |
Administracion de inhibidores de dipeptidil peptidasa
|
WO2007033266A2
(en)
*
|
2005-09-14 |
2007-03-22 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors for treating diabetis
|
TW200745080A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
|
KR101368988B1
(ko)
*
|
2005-09-16 |
2014-02-28 |
다케다 야쿠힌 고교 가부시키가이샤 |
디펩티딜 펩티다제 억제제
|
TW200745079A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
|
WO2007051987A1
(en)
*
|
2005-11-01 |
2007-05-10 |
Activotec Spp Limited |
Insulinotropic compounds and uses thereof
|
AU2006313430B2
(en)
|
2005-11-08 |
2012-09-06 |
Ranbaxy Laboratories Limited |
Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
US8039432B2
(en)
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
US20080280328A1
(en)
*
|
2005-11-18 |
2008-11-13 |
Novozymes A/S |
Glucoamylase Variants
|
CA2634495A1
(en)
*
|
2005-12-22 |
2007-06-28 |
Conjuchem Biotechnologies Inc. |
Process for the production of preformed conjugates of albumin and a therapeutic agent
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
CN101379075B
(zh)
|
2006-02-08 |
2013-05-15 |
隆萨股份公司 |
类胰高血糖素肽的合成
|
JP2009531456A
(ja)
*
|
2006-03-28 |
2009-09-03 |
武田薬品工業株式会社 |
(r)−3−アミノピペリジン二塩酸塩の調製
|
ES2566058T3
(es)
|
2006-03-30 |
2016-04-08 |
Valeritas, Inc. |
Dispositivo de suministro de fluidos de múltiples cartuchos
|
DE602007009377D1
(de)
|
2006-05-30 |
2010-11-04 |
Intarcia Therapeutics Inc |
Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
|
KR100886783B1
(ko)
|
2006-06-12 |
2009-03-04 |
성균관대학교산학협력단 |
N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
|
TW200821386A
(en)
|
2006-07-18 |
2008-05-16 |
Centocor Inc |
Human GLP-1 mimetibodies, compositions, methods and uses
|
JP5102833B2
(ja)
*
|
2006-07-24 |
2012-12-19 |
バイオレクシス ファーマシューティカル コーポレーション |
エキセンディン融合タンパク質
|
US7682356B2
(en)
|
2006-08-09 |
2010-03-23 |
Intarcia Therapeutics, Inc. |
Osmotic delivery systems and piston assemblies for use therein
|
TWI430806B
(zh)
*
|
2006-09-13 |
2014-03-21 |
Smithkline Beecham Corp |
用於投與長效降血糖藥劑之方法
|
AR062760A1
(es)
*
|
2006-09-13 |
2008-12-03 |
Takeda Pharmaceutical |
Administracion de inhibidores de dipeptidilpetidasa
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
TW200838536A
(en)
*
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
AU2011254001B2
(en)
*
|
2007-01-05 |
2012-08-02 |
Covx Technologies Ireland Limited |
Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
|
US20090099074A1
(en)
*
|
2007-01-10 |
2009-04-16 |
Conjuchem Biotechnologies Inc. |
Modulating food intake
|
KR20150116465A
(ko)
|
2007-02-15 |
2015-10-15 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-항진물질
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
JP5351884B2
(ja)
|
2007-04-23 |
2013-11-27 |
インターシア セラピューティクス,インコーポレイティド |
インスリン分泌促進性ペプチドの懸濁製剤及び使用
|
WO2008154619A1
(en)
*
|
2007-06-12 |
2008-12-18 |
Smithkline Beecham Corporation |
Methods for detecting protein in plasma
|
WO2008157824A2
(en)
*
|
2007-06-21 |
2008-12-24 |
Conjuchem Biotechnologies Inc. |
Thrombopoietin peptide conjugates
|
US7960336B2
(en)
*
|
2007-08-03 |
2011-06-14 |
Pharmain Corporation |
Composition for long-acting peptide analogs
|
WO2009030738A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
US20100261637A1
(en)
|
2007-09-05 |
2010-10-14 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
JP2010538049A
(ja)
|
2007-09-05 |
2010-12-09 |
ノボ・ノルデイスク・エー/エス |
切断型glp−1誘導体及びその治療的使用
|
JP5473925B2
(ja)
*
|
2007-10-27 |
2014-04-16 |
コーデン ファーマ コロラド インコーポレイテッド |
固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成
|
EP2231191A2
(en)
*
|
2007-12-11 |
2010-09-29 |
ConjuChem Biotechnologies Inc. |
Formulation of insulinotropic peptide conjugates
|
CA2726861C
(en)
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
WO2009143285A2
(en)
|
2008-05-21 |
2009-11-26 |
Amylin Pharmaceuticals, Inc. |
Exendins to lower cholestrol and triglycerides
|
NZ589847A
(en)
|
2008-06-17 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Glucagon/glp-1 receptor co-agonists
|
EP2952202B1
(en)
|
2008-06-17 |
2017-10-18 |
Indiana University Research and Technology Corporation |
Gip-based mixed agonists for treatment of metabolic disorders and obesity
|
EP2926825A1
(en)
|
2008-06-27 |
2015-10-07 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
CN102112157B
(zh)
|
2008-08-06 |
2013-05-29 |
诺沃-诺迪斯克保健股份有限公司 |
具有延长的体内效能的缀合蛋白
|
TW201012829A
(en)
*
|
2008-09-22 |
2010-04-01 |
Ipsen Mfg Ireland Ltd |
Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
|
JP2012505637A
(ja)
|
2008-10-15 |
2012-03-08 |
アンジオケム,インコーポレーテッド |
Glp−1アゴニストのコンジュゲート及びその使用
|
RS56632B1
(sr)
|
2008-10-17 |
2018-03-30 |
Sanofi Aventis Deutschland |
Kombinacija insulina i glp-1-agonista
|
CN102307904A
(zh)
|
2008-12-05 |
2012-01-04 |
安吉奥开米公司 |
神经降压素或神经降压素类似物的缀合物及其用途
|
PL2373681T3
(pl)
|
2008-12-10 |
2017-07-31 |
Glaxosmithkline Llc |
Kompozycje farmaceutyczne albiglutydu
|
CN102292349B
(zh)
|
2009-01-22 |
2016-04-13 |
诺沃—诺迪斯克保健股份有限公司 |
稳定的生长激素化合物
|
KR20110122134A
(ko)
|
2009-02-25 |
2011-11-09 |
머크 샤프 앤드 돔 코포레이션 |
글리코공학처리된 효모 피키아 파스토리스에서 갈락토스 동화 경로의 대사 공학
|
US20120071401A1
(en)
|
2009-04-10 |
2012-03-22 |
Amylin Pharamaceuticals, Inc. |
Amylin agonist compounds for estrogen-deficient mammals
|
KR20120087875A
(ko)
|
2009-06-16 |
2012-08-07 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
Gip 수용체-활성 글루카곤 화합물
|
RU2012103240A
(ru)
*
|
2009-07-02 |
2013-08-10 |
Ангиокем Инк. |
Мультимерные пептидные конъюгаты и их применение
|
CN101987868B
(zh)
*
|
2009-07-30 |
2013-09-04 |
江苏豪森医药集团有限公司 |
Glp-1类似物的衍生物或其可药用盐和用途
|
US8841249B2
(en)
|
2009-08-06 |
2014-09-23 |
Novo Nordisk A/S |
Growth hormones with prolonged in-vivo efficacy
|
HUE035862T2
(en)
|
2009-09-28 |
2018-05-28 |
Intarcia Therapeutics Inc |
Rapid development and / or completion of substantially steady-state drug delivery
|
EP2484386B1
(en)
*
|
2009-09-30 |
2019-04-17 |
Kyoto University |
Molecular probe for pancreatic islets imaging and use of said probe
|
EP2491054A2
(en)
|
2009-10-22 |
2012-08-29 |
Cadila Healthcare Limited |
Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
|
AU2010317995B2
(en)
|
2009-11-13 |
2014-04-17 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
|
CN102711804B
(zh)
|
2009-11-13 |
2015-09-16 |
赛诺菲-安万特德国有限公司 |
包含glp-1激动剂和甲硫氨酸的药物组合物
|
KR20120116942A
(ko)
|
2009-11-23 |
2012-10-23 |
아밀린 파마슈티칼스, 인크. |
폴리펩티드 접합체
|
TWI508737B
(zh)
|
2010-01-22 |
2015-11-21 |
諾佛 儂迪克股份有限公司 |
具有延長的活體內功效的生長激素
|
US9211342B2
(en)
|
2010-01-22 |
2015-12-15 |
Novo Nordisk Healthcare Ag |
Stable growth hormone compounds resistant to proteolytic degradation
|
MX2012008603A
(es)
|
2010-01-27 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
|
JP5976549B2
(ja)
|
2010-02-24 |
2016-08-24 |
メルク・シャープ・エンド・ドーム・コーポレイション |
ピチア・パストリスにおいて産生される治療用糖タンパク質上のn−グリコシル化部位占拠を増加させるための方法
|
US20130143798A1
(en)
*
|
2010-03-26 |
2013-06-06 |
Novo Nordisk A/S |
Novel glucagon analogues
|
EP2555791B1
(en)
|
2010-04-09 |
2017-11-01 |
Sinai Health System |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
CN107129538B
(zh)
|
2010-04-27 |
2021-07-16 |
西兰制药公司 |
Glp-1受体激动剂和胃泌素的肽缀合物及其用途
|
WO2011140176A1
(en)
|
2010-05-04 |
2011-11-10 |
Glaxosmithkline Llc |
Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
|
CA2797089A1
(en)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
|
CA2797095A1
(en)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
|
JP6199186B2
(ja)
|
2010-08-30 |
2017-09-20 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
2型糖尿病の治療用の医薬の製造のためのave0010の使用
|
EP3326620B1
(en)
|
2010-12-16 |
2020-03-04 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
|
BR112013015389A2
(pt)
|
2010-12-22 |
2016-11-22 |
Univ Indiana Res & Tech Corp |
análogo de glucagon exibindo atividade de receptor gip
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
JP6189754B2
(ja)
|
2011-03-04 |
2017-08-30 |
イントレキソン コーポレーション |
タンパク質を条件的に発現するベクター
|
HUE031405T2
(en)
|
2011-04-12 |
2017-07-28 |
Novo Nordisk As |
Double-acylated GLP-1 derivatives
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
RU2014101697A
(ru)
|
2011-06-22 |
2015-07-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Коагонисты рецепторов глюкагона/glp-1
|
CN103857408B
(zh)
|
2011-06-22 |
2017-04-12 |
印第安那大学科技研究公司 |
胰高血糖素/glp‑1受体协同激动剂
|
KR101357117B1
(ko)
*
|
2011-06-28 |
2014-02-06 |
비앤엘델리팜 주식회사 |
폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
|
JP6367115B2
(ja)
|
2011-08-29 |
2018-08-01 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
2型糖尿病患者の血糖コントロールに使用する組合せ医薬
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
CN103189389B
(zh)
*
|
2011-09-03 |
2017-08-11 |
深圳市健元医药科技有限公司 |
新的glp‑ⅰ类似物及其制备方法和用途
|
CN102286092B
(zh)
*
|
2011-09-14 |
2014-01-01 |
深圳翰宇药业股份有限公司 |
利拉鲁肽的固相合成方法
|
CA2849673A1
(en)
|
2011-09-23 |
2013-03-28 |
Novo Nordisk A/S |
Novel glucagon analogues
|
WO2013064669A1
(en)
|
2011-11-03 |
2013-05-10 |
Zealand Pharma A/S |
Glp-1 receptor agonist peptide gastrin conjugates
|
US9499587B2
(en)
*
|
2012-01-23 |
2016-11-22 |
University Of South Florida |
Gamma-AApeptides with potent and broad-spectrum antimicrobial activity
|
PT2827845T
(pt)
|
2012-03-22 |
2019-03-29 |
Novo Nordisk As |
Composições compreendendo um agente de entrega e sua preparação
|
MY171146A
(en)
|
2012-03-22 |
2019-09-27 |
Novo Nordisk As |
Compositions of glp-1 peptides and preparation thereof
|
WO2013163162A1
(en)
*
|
2012-04-24 |
2013-10-31 |
Amylin Pharmaceuticals, Llc |
Site-specific enzymatic modification of exendins and analogs thereof
|
US9289507B2
(en)
|
2012-05-17 |
2016-03-22 |
Extend Biosciences, Inc. |
Carriers for improved drug delivery
|
EP2863895B1
(en)
|
2012-06-20 |
2021-04-14 |
Novo Nordisk A/S |
Tablet formulation comprising a peptide and a delivery agent
|
EP2864351B1
(en)
|
2012-06-21 |
2016-08-10 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
CN104582736A
(zh)
|
2012-06-21 |
2015-04-29 |
印第安纳大学研究及科技有限公司 |
Fc效应子功能改变的肠降血糖素受体配体多肽Fc区融合多肽和缀合物
|
CN104662038B
(zh)
|
2012-07-23 |
2018-11-06 |
西兰制药公司 |
胰高血糖素类似物
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
BR112015014510A2
(pt)
|
2012-12-21 |
2017-11-21 |
Sanofi Sa |
agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
WO2014124487A1
(en)
|
2013-02-18 |
2014-08-21 |
Vegenics Pty Limited |
Ligand binding molecules and uses thereof
|
US20160024169A1
(en)
|
2013-03-14 |
2016-01-28 |
Indiana University Research And Technology Corporation |
Insulin-incretin conjugates
|
CN104650212A
(zh)
*
|
2013-03-15 |
2015-05-27 |
深圳君圣泰生物技术有限公司 |
一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用
|
CN104592380A
(zh)
*
|
2013-03-15 |
2015-05-06 |
深圳君圣泰生物技术有限公司 |
一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用
|
AR095986A1
(es)
*
|
2013-04-03 |
2015-11-25 |
Sanofi Sa |
Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
|
WO2014166836A1
(en)
|
2013-04-05 |
2014-10-16 |
Novo Nordisk A/S |
Growth hormone compound formulation
|
KR20160021758A
(ko)
|
2013-04-18 |
2016-02-26 |
노보 노르디스크 에이/에스 |
의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트
|
CN105745222A
(zh)
|
2013-10-17 |
2016-07-06 |
西兰制药公司 |
酰化胰高血糖素类似物
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
TWI670281B
(zh)
|
2013-11-06 |
2019-09-01 |
西蘭製藥公司 |
Gip-glp-1雙重促效劑化合物及方法
|
CA2929107C
(en)
|
2013-11-06 |
2023-09-26 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
TW201609795A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物
|
WO2015086729A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/gip receptor agonists
|
EP3080149A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
WO2015086730A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
CN106029087A
(zh)
|
2013-12-20 |
2016-10-12 |
印第安纳大学研究及科技有限公司 |
脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
|
CN112957455A
(zh)
|
2014-01-09 |
2021-06-15 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
|
MX2016008978A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
|
CN105899190B
(zh)
|
2014-01-09 |
2022-06-14 |
赛诺菲 |
门冬胰岛素的稳定化药物制剂
|
WO2015138638A1
(en)
|
2014-03-11 |
2015-09-17 |
Theraly Pharmaceuticals, Inc. |
Long acting trail receptor agonists for treatment of autoimmune diseases
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
US10570184B2
(en)
|
2014-06-04 |
2020-02-25 |
Novo Nordisk A/S |
GLP-1/glucagon receptor co-agonists for medical use
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
WO2016049190A1
(en)
|
2014-09-24 |
2016-03-31 |
Indiana University Research And Technology Corporation |
Incretin-insulin conjugates
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
EP3220961B1
(en)
|
2014-10-22 |
2023-07-05 |
Extend Biosciences, Inc. |
Therapeutic vitamin d conjugates
|
WO2016065052A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Insulin vitamin d conjugates
|
ES2883345T3
(es)
|
2014-10-29 |
2021-12-07 |
Zealand Pharma As |
Compuestos agonistas del GIP y métodos
|
MX2017007699A
(es)
|
2014-12-12 |
2017-09-18 |
Sanofi Aventis Deutschland |
Formulacion de proporcion fija de insulina glargina/lixisenatida.
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
JP6989385B2
(ja)
|
2015-04-16 |
2022-01-05 |
ジーランド ファーマ アクティーゼルスカブ |
アシル化グルカゴン類似体
|
ES2968262T3
(es)
|
2015-06-03 |
2024-05-08 |
I2O Therapeutics Inc |
Sistemas de colocación de implantes
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
ES2826827T3
(es)
|
2015-06-15 |
2021-05-19 |
Angiochem Inc |
Métodos para el tratamiento de carcinomatosis leptomeníngea
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
EA038551B1
(ru)
|
2015-12-17 |
2021-09-14 |
Дзе Джонс Хопкинс Юниверсити |
Способ лечения или профилактики системного склероза
|
WO2017112889A1
(en)
|
2015-12-23 |
2017-06-29 |
The Johns Hopkins University |
Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
|
WO2017177148A1
(en)
|
2016-04-07 |
2017-10-12 |
The Johns Hopkins University |
Compositions and methods for treating pancreatitis and pain with death receptor agonists
|
WO2017200943A1
(en)
|
2016-05-16 |
2017-11-23 |
Intarcia Therapeutics, Inc. |
Glucagon-receptor selective polypeptides and methods of use thereof
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
CN108070030B
(zh)
*
|
2016-11-17 |
2023-06-23 |
江苏豪森药业集团有限公司 |
洛塞那肽及其类似物的制备方法
|
BR112019010624A2
(pt)
|
2016-12-09 |
2019-10-22 |
Zealand Pharma As |
agonistas duplos de glp-1/glp-2 acilados e composição
|
CN110225762A
(zh)
|
2017-01-03 |
2019-09-10 |
因塔西亚制药公司 |
包括glp-1受体激动剂的连续施用和药物的共同施用的方法
|
JOP20180028A1
(ar)
|
2017-03-31 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركب ببتيد
|
CN109503700A
(zh)
*
|
2017-09-14 |
2019-03-22 |
南京安吉生物科技有限公司 |
马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
|
US10905750B2
(en)
|
2017-11-10 |
2021-02-02 |
Donald J. Davidson |
GRP78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents
|
KR102647171B1
(ko)
|
2018-02-02 |
2024-03-15 |
노보 노르디스크 에이/에스 |
Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
|
WO2019200594A1
(zh)
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
WO2020077129A1
(en)
|
2018-10-11 |
2020-04-16 |
Intarcia Therapeutics, Inc. |
Human amylin analog polypeptides and methods of use
|
CN109400695B
(zh)
|
2018-10-31 |
2020-06-30 |
中南大学湘雅医院 |
一种多肽的修饰方法及应用
|
CN110183531A
(zh)
*
|
2019-05-17 |
2019-08-30 |
河北常山生化药业股份有限公司 |
一种艾本那肽前体的制备方法
|
CN111333714A
(zh)
*
|
2020-03-05 |
2020-06-26 |
成都奥达生物科技有限公司 |
一种长效glp-1化合物
|
JP2023520989A
(ja)
*
|
2020-03-27 |
2023-05-23 |
エピバックス・インコーポレーテッド |
1型糖尿病の予防および治療に有用なtレジトープ構築物
|